Heterocyclic Building Blocks-piperazine

On August 18, 1975, there was a patent about cycloaddition reaction.Recommanded Product: 53788-12-8 The title of the patent was p-Dithiino[2,3-c]pyrroles. And the patent contained the following:

Dithiinopyrroles I (R = OH, OMe, R1 = H; R = Me, R1 = H, Me, Cl, OMe; R = H, R1 = Cl, Me, OMe) were prepared by treating the 2-aminonaphthyridines with 5,6-dihydro-1,4-dithiin-2,3-dicarboxylic anhydride, chlorinating when R1 = OH, reducing the dithiinopyrroledione to the monohydroxy derivative, and treating the latter with chlorocarbonylpiperazines. II (R2 = Et, CHMe2, allyl, CH2CH2OH) were similarly prepared The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 53788-12-8

The Article related to dithiinopyrrolol piperazinecarboxylate naphthyridinyl pyridinyl, piperazinecarboxylate naphthyridinyldithiinopyrrolyl, pyridinyldithiinopyrrolyl piperazinecarboxylate, aminonaphthyridine dithiindicarboxylate condensation and other aspects.Recommanded Product: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 16, 2021, Ewin, Richard Andrew; Cox, Mark R.; Hot, Imelda; Bedore, Matthew W.; Respondek, Tomasz; Sheehan, Susan M.K. published a patent.Recommanded Product: 53788-12-8 The title of the patent was Preparation of heteroaryl azalide glycosides as immunomodulators. And the patent contained the following:

Defined herein are immunomodulating heteroaryl azalide glycosides I, stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein W is H, sugar residue; RingC is Ph, naphthyl, 5-6 membered monocyclic heteroaryl ring or 9-11 membered fused heteroaryl ring; R1 is substituted benzyl, CH2-heteroaryl; R2 is H, alkyl, acyl, substituted amide, alkylaryl, alkyl-heterocycle; R3 is alkyl, alkoxy, haloalkyl, haloalkoxy, alkyl-cycloalkyl, halogen, substituted amine, substituted amide, substituted sulfoxide, nitro, oxo, cyano, -C(O)H, acyl, carboxylate, oxo-carboxylate, OH, heterocyclic, heteroaryl; n is an integer 0-3; and pharmaceutically acceptable salts thereof; and compositions comprising said compounds Thus, heteroaryl azalide glycoside II was prepared The invention also includes methods for treating an inflammatory and/or immunol. disease or disorder in an animal by administering a therapeutically effective amount of compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compounds to prepare a medicament for treating an inflammatory and/or immunol. disease or disorder in an animal. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 53788-12-8

The Article related to polonovski demethylation aminoglycoside preparation human antiinflammatory, il1 cd163 tnf nfkb azithromycin macrolide aminoglycoside preparation human, immunomodulating hetero aryl tlr4 toll like receptor antiinflammatory and other aspects.Recommanded Product: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Saydam, Guray; Ali, Ridvan; Demir, Ahmet Muzaffer; Eskazan, Ahmet Emre; Guvenc, Birol; Haznedaroglu, Ibrahim Celalettin; Ozcan, Mehmet Ali; Salim, Ozan; Sonmez, Mehmet; Tuglular, Ayse Tulin; Turgut, Mehmet; Unal, Ali; Aver, Birkan; Bozkurt, Sirac; Ozdengulsun, Begum; Ilhan, Osman published an article in 2022, the title of the article was The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.HPLC of Formula: 380843-75-4 And the article contains the following content:

A review. Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clin. approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient’s individual condition. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4

The Article related to review chronic myeloid leukemia comorbidity tki nilotinib ponatinib dasatinib, adverse event, chronic myeloid leukemia, comorbidity, drug toxicity, interactions (drug–drug), safety, tolerability, tyrosine kinase inhibitor and other aspects.HPLC of Formula: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 12, 2018, Crew, Andrew P.; Hornberger, Keith R.; Snyder, Lawrence B.; Zimmermann, Kurt; Wang, Jing; Berlin, Michael; Crews, Craig M.; Dong, Hanqing published a patent.Category: piperazines The title of the patent was Preparation of bifunctional compounds for the targeted degradation of androgen receptor. And the patent contained the following:

The invention relates to bifunctional compounds, which find utility to degrade and (inhibit) androgen receptor. In particular, the invention is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds androgen receptor, such that androgen receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of androgen receptor. The invention exhibits a broad range of pharmacol. activities associated with compounds according to the present invention, consistent with the degradation/inhibition of androgen receptor (data given). The invention compounds are claimed to be useful for the treatment of cancer or Kennedy’s disease, or both. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).Category: piperazines

The Article related to protac modulator preparation targeted ubiquitination androgen receptor degradation inhibition, preparation bifunctional compound degradation androgen receptor, treatment cancer kennedy disease preparation bifunctional compound and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 1, 2017, Lin, Xiao-Xiao; Zhang, Xiao-Fang; Wang, Ai-Jun; Fang, Ke-Ming; Yuan, Junhua; Feng, Jiu-Ju published an article.Computed Properties of 67914-60-7 The title of the article was Simple one-pot aqueous synthesis of AuPd alloy nanocrystals/reduced graphene oxide as highly efficient and stable electrocatalyst for oxygen reduction and hydrogen evolution reactions. And the article contained the following:

Herein, the authors develop a simple 1-pot aqueous method to prepare AuPd alloy nanocrystals on reduced graphene oxide (AuPd NCs/rGO), by using 1-acetyl-4-(p-hydroxyphenyl) piperazine (AHPP) as the reductant, stabilizing agent and structure-director, without any other additives (e.g., seed, surfactant or polymer). The product is mainly characterized by TEM, XPS, x-ray diffraction and TGA. The obtained AuPd NCs/rGO displays enlarged electrochem. active surface area and superior catalytic performances toward O reduction reaction (ORR) and H evolution reaction (HER) relative to Pt/C, Pd/C, Pd/rGO and Au/rGO catalysts, showing promising applications in energy storage and conversion. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Computed Properties of 67914-60-7

The Article related to synthesis gold palladium alloy nanocrystal reduced graphene oxide catalyst, electrocatalyst oxygen reduction hydrogen evolution, aupd nanocrystals, hydrogen evolution reaction, oxygen reduction reaction, reduced graphene oxide and other aspects.Computed Properties of 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 15, 2006, Power, Eoin C.; Ganellin, C. Robin; Benton, David C. H. published an article.Application of 67914-60-7 The title of the article was Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BKCa). And the article contained the following:

A series of partial structures of ketoconazole has been synthesized and tested for activity on the large conductance calcium-activated potassium channel (BK) in bovine smooth muscle cells. This has provided openers and blockers of the channel. The results suggest that the Ph and phenoxy moieties are important for interaction with BK, whereas the imidazole group is unimportant. The properties of the phenoxy moiety seem to determine whether the compounds act to open or block the channel. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Application of 67914-60-7

The Article related to potassium channel calcium activated large conductance ketoconazole fragment preparation, kcnm family potassium channel ketoconazole fragment preparation, channel blocker opener potassium calcium ketoconazole analog preparation and other aspects.Application of 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 30, 2021, Mizuno, Takahito; Sakai, Takamasa; Tanabe, Kouichi; Kozaki, Koji; Umemura, Takumi; Higashikawa, Mariko; Kimura, Tomoki; Yamada, Tetsuya; Goto, Nobuyuki; Ohtsu, Fumiko published an article.Category: piperazines The title of the article was Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: An investigation of real world data. And the article contained the following:

Purpose: In order to detect cancer therapeutics-related cardiac dysfunction (CTRCD) early, we identified which drugs were to be monitored using signal detection and the package insert, and created and applied a protocol to address this. Methods: Adverse event data recorded in the Japanese Adverse Drug Event Report (JADER) database between Apr. 2004 and Jan. 2018 were used. We applied our findings clin. by creating a protocol to detect CTRCD early. All cases at Tosei General Hospital where the target tyrosine kinase inhibitors were administered from when they were first released in Nov. 2019 were included. We compared the results from before and after we began the protocol to clarify its effects. Results: We found that CTRCD was not described in the serious side-effect section of the package inserts for Bosutinib, Alectinib, and Osimertinib even though CTRCD signals were detected for them. Therefore, it is possible that we may have previously overlooked CTRCD. When we applied our protocol using Osimertinib as the target drug, we were able to detect CTRCD early in 5/21 (24%) patients. Conclusions: It was clarified that the drug identification method used in this study for early detection of adverse events leads to early detection of adverse events when applied clin. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to cancer cardiac dysfunction tyrosine kinase inhibitor therapeutics side effect, cancer therapeutics-related cardiac dysfunction, japanese adverse drug event report database, osimertinib, small molecule tyrosine kinase inhibitors and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 30, 2020, Pushpam, Deepam; Bakhshi, Sameer published an article.Computed Properties of 380843-75-4 The title of the article was Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective. And the article contained the following:

Meta-anal. of tyrosine kinase inhibitors pharmacol. in chronic myeloid leukemia patients. Upcoming concepts and related trials in the management of chronic myeloid leukemia (CML) along with future directions have been touched upon. Evidence acquisition: PubMed, Embase, Google, Cochrane library and Medline were searched to identify relevant literature for the review. Clinicaltrial.gov was searched for upcoming data and trials. Results: There are lot of gap in pharmacokinetics and pharmacodynamics of TKI. Imatinib appears to be the safest TKI. Newer TKI’s achieve better achievement of therapeutic milestones, deeper mol. response and less chances of progression of CML compared to imatinib. Newer TKI appears to be better choice for achieving TFR. When the objective is survival, imatinib is still the TKI of choice. Primary prophylaxis with antiplatelet drugs for TKI having cardiovascular and thromboembolic side effects should be considered. Conclusion: Pharmacogenetic data of TKI is still immature to guide in therapeutic decision making in clin. practice. There is need for further research in pharmacol. and pharmacogenomics of newer TKI’s. Randomized controlled trials are required to decide the optimum TKI for TFR. Safe and effective TKI for targeting T315I mutation, CML accelerated phase and blast crisis are an active area of research. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to meta analysis chronic myeloid leukemia tyrosine kinase pharmacol, gene polymorphism and imatinib, pharmacology of tyrosine kinase inhibitors, selection of tyrosine kinase inhibitors, tyrosine kinase inhibitors in chronic myeloid leukemia and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 1, 2017, Xiao, Ganyuan; Li, Yan; Qiang, Xiaoming; Xu, Rui; Zheng, Yunxiaozhu; Cao, Zhongcheng; Luo, Li; Yang, Xia; Sang, Zhipei; Su, Fu; Deng, Yong published an article.Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride The title of the article was Design, synthesis and biological evaluation of 4′-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease. And the article contained the following:

A series of 4′-aminochalcone-revastigmine hybrids were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer’s disease. The results showed that most of these compounds exhibited good multifunctional activities. In particular, compound 6c displayed the best inhibitory potency on acetylcholinesterase (IC50 = 4.91 μM), and significant antioxidative activity with a value 2.83-fold of Trolox. The kinetic anal. of AChE inhibition revealed that 6c showed mixed-type inhibition, binding simultaneously to the catalytic active site and peripheral anionic site of AChE. In addition, 6c inhibited self-induced Aβ1-42 aggregation and Cu2+-induced Aβ1-42 aggregation by 89.5% and 79.7% at 25 μM resp., as well as acted as a selective monoamine oxidase B inhibitor (IC50 = 0.29 μM) and a selective biometal chelator. Furthermore, 6c could cross the blood-brain barrier in vitro. Based on these results, Compound 6c could be considered as a very promising lead compound for Alzheimer’s disease. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to aminochalcone revastigmine hybrid synthesis blood brain barrier alzheimer disease, acetylcholinesterase inhibitors, alzheimer’s disease, aβ aggregation inhibitors, chalcone carbamate derivatives, monoamine oxidase b inhibitors, multifunctional agents and other aspects.Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 1, 2020, Koller, Dora; Vaitsekhovich, Viktoryia; Mba, Cecile; Steegmann, Juan L.; Zubiaur, Pablo; Abad-Santos, Francisco; Wojnicz, Aneta published an article.Computed Properties of 380843-75-4 The title of the article was Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. application to therapeutic drug monitoring. And the article contained the following:

Therapeutic drug monitoring (TDM) help to improve treatment efficacy and safety. Therefore, a simple and sensitive liquid chromatog.-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous monitoring of 11 tyrosine kinase inhibitors (TKIs) in human plasma. TKIs included in the assay are used in the treatment of chronic myeloid leukemia (CML: imatinib, dasatinib, nilotinib, bosutinib, ponatinib), polycythemia vera (ruxolitinib), chronic lymphocytic leukemia (ibrutinib) and rheumatoid arthritis (filgotinib, tofacitinib, baricitinib, peficitinib). Caffeine was also included in the method. Caffeine increases the acidity of the stomach and decreases its pH as well as is a competitive inhibitor of cytochrome P 450 isoenzymes. Thus, it may influence absorption and metabolism of some TKIs, by modifying their plasma levels. The analytes of interest and their stable isotope-labeled internal standards were extracted from 200μL of human plasma. Microelution-solid phase extraction (μ-SPE) was optimized for method validation and compared to simple protein precipitation (PPT). A gradient elution on a Poroshell 120 EC-C18 column at 60°C and a flow rate of 0.5 mL/min was applied for analyte separation The anal. run lasted 8 min and it was followed by a re-equilibration time of 4 min. Dynamic multiple reaction monitoring scan in the pos. ionization mode was applied to improve method sensitivity. Endogenous plasma phospholipids can strongly affect MS anal. Hence, the monitoring of endogenous phospholipids was included in the assay. Full validation of the method was achieved, including tests of precision, accuracy, trueness, linearity, extraction recovery, matrix effect, process efficiency, stability, sensitivity (with excellent LLOQs), selectivity, identity confirmation and carry-over effect. Regarding sample cleanup, more than 91% of early eluting and more than 96% of late eluting endogenous phospholipids were eliminated by μ-SPE when compared to PPT. This method enables the simultaneous plasma monitoring of 11 TKIs and caffeine and ensures high effectiveness in phospholipids elimination. The present approach is currently used in our clin. practice, being applied to TDM of dasatinib, imatinib, nilotinib and ponatinib. TKIs plasma monitoring helps to individualize dose adjustment and manage adverse effects in CML patients. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to tyrosine kinase inhibitor therapeutic drug monitoring hplc mass spectrometry, blood plasma analysis, caffeine, liquid chromatography-tandem mass spectrometry, phospholipids, solid phase extraction, therapeutic drug monitoring, tyrosine kinase inhibitors and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics